Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells

Tracey D. Bradshaw*, Marc Junor, Amalia Patanè, Phil Clarke, Neil R. Thomas, Mei Li, Stephen Mann, Lyudmila Turyanska

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

12 Citations (Scopus)

Abstract

Colorectal carcinoma (CRC) is the 3rd most common cancer worldwide, thus development of novel therapeutic strategies is imperative. Herein potent, selective dose-dependent antitumor activity of horse spleen apoferritin encapsulated PbS quantum dots (AFt-PbS) against two human-derived colorectal carcinoma cell lines is reported (GI50 ∼ 70 μg mL-1). Following in vitro exposure to AFt-PbS, CRC cells fail to recover proliferative capacity, and undergo apoptosis triggered by the generation of reactive oxygen species (ROS). In stark contrast, the AFt-PbS nanocomposites do not affect the growth and cell cycle of non-tumor human microvessel endothelial HMEC-1 cells (GI50 > 500 μg mL -1). In vivo, AFt-PbS QDs are well tolerated by mice. Neither adverse health nor behavioral indicators were observed throughout the 15 day study. The photoluminescence of AFt-PbS combined with selective antitumor activity offer potential development of AFt-PbS for simultaneous non-invasive imaging and treatment of malignant tissue. This journal is

Original languageEnglish
Pages (from-to)6254-6260
Number of pages7
JournalJournal of Materials Chemistry B
Volume1
Issue number45
DOIs
Publication statusPublished - 7 Dec 2013

Fingerprint Dive into the research topics of 'Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells'. Together they form a unique fingerprint.

  • Cite this